ArticleClinical, cosmetic and investigational dermatology2026
Genetically Predicted Serum miRNAs as Potential Causal Drivers of Atopic Dermatitis: Evidence from Large-Scale GWAS and Clinical Validation.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although dysregulated microRNAs (miRNAs) are implicated in Atopic Dermatitis (AD), their causal roles remain elusive due to potential confounding and reverse causation. We aimed to systematically identify causal miRNAs for AD and elucidate their underlying mechanisms. Methods: We conducted a bidirectional two-sample Mendelian randomization (MR) study using large-scale GWAS summary statistics for 2083 miRNAs and AD. The findings were validated using independent trans- and cis-eQTL datasets, and consistency was assessed via correlation analysis. Bayesian colocalization was applied to distinguish pleiotropy from linkage disequilibrium. Downstream targets were analyzed via GO/KEGG enrichment, and clinical relevance was verified using differential expression analysis in two independent patient cohorts (GSE162926 and GSE217232). Results: We identified six circulatory miRNAs causally associated with AD. Notably, miR-1908-5p, miR-148a-3p, miR-133a-3p were identified as a robust risk factor, while miR-125a-5p, miR-181b-5p, let-7e-5p exhibited a protective effect. Colocalization analysis revealed compelling evidence (PP.H4=0.99) for a shared causal variant (rs174561) between miR-1908-5p and AD. Reverse MR indicated no causal effect of AD on these miRNAs. Functional enrichment analyses revealed that downstream targets were predominantly enriched in the PI3K-Akt and MAPK signaling pathways, regulating biological processes critical for skin barrier integrity, wound healing, and oxidative stress response. Crucially, transcriptomic analysis in clinical cohorts corroborated the MR findings, showing significant dysregulation of the identified miRNAs in AD patients. Conclusion: This study provides robust genetic and transcriptomic evidence for the causal involvement of specific circulating miRNAs, particularly miR-1908-5p, in AD pathogenesis. These findings offer potential novel biomarkers and therapeutic targets for precision medicine in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.